Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.
Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.
J Gynecol Obstet Hum Reprod. 2022 Jan;51(1):102256. doi: 10.1016/j.jogoh.2021.102256. Epub 2021 Oct 20.
The aim of the present study was to evaluate the prognostic impact of peritoneal washing cytology (PWC) on progression-free (PFS) and overall survival (OS) of patients undergoing interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) for ovarian cancer (OC).
We systematically searched Medline (1966-2020), Scopus (2004-2020), EMBASE (1980-2020), Cochrane Central Register of Controlled Trials CENTRAL (1999-2020), Clinicaltrials.gov (2008-2020) and Google Scholar (2004-2020). All the studies that investigated the correlation of peritoneal washing cytology with survival outcomes of patients undergoing interval debulking for ovarian cancer, were finally included in the present meta-analysis.
A total of 7 retrospective studies were included, comprising 907 patients, of whom 535 had positive peritoneal washing cytology on interval debulking surgery. The methodological quality of the included studies was assessed as moderate, primarily due to the lack of data referring to the adequacy of the follow-up of patients and secondarily due the lack of comparability of patients. Progression - free survival was significantly better in the negative peritoneal cytology group (HR 2.07, 95% CI 1.73, 2.48 respectively), however, overall survival did not reach a significant difference among the two groups (HR 1.90, 95% CI 0.99, 3,65, p = 0.052).
Our data support a negative correlation between positive peritoneal washing cytology at interval debulking surgery and the survival of ovarian cancer patients.
本研究旨在评估新辅助化疗（NACT）后间隔减瘤手术（IDS）时腹膜冲洗细胞学（PWC）对卵巢癌（OC）患者无进展生存期（PFS）和总生存期（OS）的预后影响。
我们系统地检索了 Medline（1966-2020 年）、Scopus（2004-2020 年）、EMBASE（1980-2020 年）、Cochrane 中央对照试验注册中心 CENTRAL（1999-2020 年）、Clinicaltrials.gov（2008-2020 年）和 Google Scholar（2004-2020 年）。最终纳入了所有研究腹膜冲洗细胞学与卵巢癌间隔减瘤患者生存结果相关性的研究进行荟萃分析。
共纳入 7 项回顾性研究，共纳入 907 例患者，其中 535 例在间隔减瘤术中腹膜冲洗细胞学阳性。纳入研究的方法学质量被评估为中等，主要是因为缺乏关于患者随访充分性的数据，其次是因为患者之间缺乏可比性。阴性腹膜细胞学组的无进展生存期明显更好（HR 2.07，95%CI 1.73，2.48），然而，两组之间的总生存期差异无统计学意义（HR 1.90，95%CI 0.99，3.65，p=0.052）。
我们的数据支持在间隔减瘤手术时腹膜冲洗细胞学阳性与卵巢癌患者的生存之间存在负相关。
